Bausch Health Cos (NYSE:BHC) Shares Gap Down – Time to Sell?

Bausch Health Cos Inc. (NYSE:BHC)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $6.19, but opened at $5.71. Bausch Health Cos shares last traded at $5.9850, with a volume of 1,540,027 shares trading hands.

Key Stories Impacting Bausch Health Cos

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Completed strategic actions that strengthen the balance sheet and China footprint — Bausch closed the Shibo aesthetics distribution acquisition in China (Dec 1, 2025) and executed a $1.7B debt exchange plus $9.6B of refinancing during 2025, extending maturities and reducing near‑term roll‑over risk. Bausch Health announces Q4 and FY2025 results
• Positive Sentiment: Product durability in dental portfolio — OraPharma marked 25 years of ARESTIN (minocycline HCl) microspheres, underscoring a long‑standing, FDA‑approved revenue stream in the dental channel. Stable legacy products reduce revenue volatility. OraPharma celebrates 25 years of ARESTIN
• Neutral Sentiment: Revenue and adjusted EBITDA trends look healthy — Q4 revenue was roughly $2.78–2.80B (reported +9% year‑over‑year; organic +6%) and consolidated adjusted EBITDA rose; the company reported stronger cash flow generation for the year. These metrics support the company’s longer‑term operational improvement narrative. Bausch Health announces Q4 and FY2025 results
• Neutral Sentiment: 2026 revenue outlook modestly positive — management is guiding ~3% revenue growth for 2026 and provided a revenue range (~$10.6B–$10.9B) that is roughly in line or slightly above consensus, which could support topline stability even if margins remain pressured. Bausch Health expects 3% revenue growth in 2026
• Neutral Sentiment: Investor materials and call transcripts available — full earnings presentation and call transcript provide detail on segment performance, China strategy, and refinancing progress (useful if you model FY2026 cash interest and maturity schedule). Q4 results presentation Earnings call transcript
• Negative Sentiment: EPS missed expectations — Q4 EPS came in at $1.08 vs. consensus ~$1.21, a notable shortfall that drove negative near‑term sentiment despite the topline beat. BHC Q4 earnings lag estimates
• Negative Sentiment: Share price reacted negatively — market headlines and coverage emphasize the EPS shortfall, prompting a sell‑off; several outlets note shares fell following the earnings release. That reaction reflects investor focus on near‑term profitability and EPS guidance ambiguity. Shares fall after earnings miss

Analyst Ratings Changes

A number of equities research analysts recently commented on BHC shares. Raymond James Financial reiterated a “market perform” rating on shares of Bausch Health Cos in a report on Monday, January 26th. Truist Financial upped their price objective on shares of Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a research note on Wednesday, January 7th. Wall Street Zen cut Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Barclays began coverage on Bausch Health Cos in a report on Monday, December 8th. They set an “equal weight” rating and a $8.00 price target on the stock. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Bausch Health Cos in a report on Monday, December 29th. Five investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $8.67.

Bausch Health Cos Stock Down 0.1%

The company’s fifty day simple moving average is $6.66 and its 200 day simple moving average is $6.69. The company has a quick ratio of 0.97, a current ratio of 1.30 and a debt-to-equity ratio of 57.48. The firm has a market capitalization of $2.29 billion, a PE ratio of 6.42 and a beta of 0.42.

Institutional Trading of Bausch Health Cos

Several institutional investors have recently added to or reduced their stakes in BHC. Caption Management LLC raised its stake in Bausch Health Cos by 101.1% during the 4th quarter. Caption Management LLC now owns 4,464 shares of the company’s stock valued at $31,000 after buying an additional 405,789 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in Bausch Health Cos by 12,589.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after purchasing an additional 4,910 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in shares of Bausch Health Cos by 6,661.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after purchasing an additional 5,329 shares during the period. Russell Investments Group Ltd. increased its position in shares of Bausch Health Cos by 65.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after purchasing an additional 3,106 shares during the last quarter. Finally, Camelot Portfolios LLC bought a new position in shares of Bausch Health Cos in the 4th quarter worth approximately $59,000. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.